- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00282139
Aripiprazole in the Treatment of Tourette's Syndrome
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
DSM-IV primary diagnosis of Tourette's syndrome or chronic tic disorder;
"Moderate" severity as reflected on the CGI or the YGTSS;
Normal ECG; and,
Written informed consent/assent.
Exclusion Criteria:
Female subjects of childbearing potential who are not practicing an effective method of birth control (including abstinence);
Subjects who are pregnant or nursing women;
Subjects with known seizure disorder, a history or seizures or with conditions that lower seizure threshold;
Subjects who currently meet DSM-IV criteria for: Schizophrenia, Schizoaffective Disorder, Delusional Disorder, or Psychotic Disorder Not Otherwise Specified;
Subjects with a Psychoactive Substance Abuse disorder (within the past 3 months);
Subjects with known allergy or hypersensitivity to aripiprazole;
Subjects who have any depot neuroleptic within one treatment cycle or any other changes in psychoactive medications (with the exception of antidepressants) in one month and two months for antidepressants prior to study entry for first administration of study medication;
Subjects who have clinically significant abnormalities based on physical examination, medical history, ECG, or laboratory tests; and,
Subjects on medication that pose drug interaction potential with aripiprazole such as carbamazepine, ketoconazole, paroxetine, and fluoxetine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Global improvement in severity of symptoms (tic behaviors)
|
Secondary Outcome Measures
Outcome Measure |
---|
Assessment of behavior (improvement and severity) for co-morbid conditions, OCD and/or ADHD
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tanya K Murphy, M.D., University of Florida
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Disease
- Genetic Diseases, Inborn
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Heredodegenerative Disorders, Nervous System
- Neurodevelopmental Disorders
- Tic Disorders
- Syndrome
- Tourette Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agonists
- Dopamine Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Aripiprazole
Other Study ID Numbers
- TSARIP703 / WIRB #20031378
- 00040256/00042966
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tourette's Syndrome
-
Weill Medical College of Cornell UniversityUniversity of California, Los Angeles; University of Wisconsin, MilwaukeeCompletedTourette's Syndrome | Tourette's Disorder | Tourette Disorder | Gilles de la Tourette Syndrome | Tourette's Disease | Tourette Disease | Tic Disorder, Combined Vocal and Multiple Motor | Multiple Motor and Vocal Tic Disorder, Combined | Gilles de La Tourette's Disease | Gilles De La Tourette's Syndrome | Combined... and other conditions
-
Otsuka Pharmaceutical Development & Commercialization...TerminatedTourette's Disorder (TD)United States, Canada, Hungary
-
Emalex Biosciences Inc.Psyadon PharmaCompleted
-
The University of Western AustraliaSir Charles Gairdner Hospital; Perron Institute for Neurological and Translational...WithdrawnTourette's SyndromeAustralia
-
University Hospital, Clermont-FerrandCompletedGilles de la Tourette's SyndromeFrance
-
Groupe Hospitalier Pitie-SalpetriereInstitut National de la Santé Et de la Recherche Médicale, FranceCompleted
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Ministry of Health, ItalyCompletedTourette Syndrome | Tourette's Syndrome | Tourette Disorder | Gilles de la Tourette SyndromeItaly
-
China Medical University HospitalBened Biomedical Co., Ltd.RecruitingTourette's SyndromeTaiwan
-
Bausch Health Americas, Inc.Withdrawn
-
Xuanwu Hospital, BeijingNot yet recruiting
Clinical Trials on Aripiprazole
-
National Institute on Alcohol Abuse and Alcoholism...Brown UniversityCompleted
-
Otsuka Beijing Research InstituteCompleted
-
H. Lundbeck A/SOtsuka Pharmaceutical Co., Ltd.CompletedSchizophreniaUnited States
-
University of California, Los AngelesAlkermes, Inc.TerminatedSchizophrenia | Schizophreniform Disorder | Schizoaffective Disorder, Depressive TypeUnited States
-
Otsuka Pharmaceutical Co., Ltd.CompletedMajor Depressive DisorderJapan
-
Veterans Medical Research FoundationBristol-Myers SquibbCompleted
-
Otsuka Pharmaceutical Co., Ltd.CompletedSchizophreniaJapan
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaKorea, Republic of, United States, Estonia, Italy, Hungary, Bulgaria, Croatia, France, Poland, Thailand, Puerto Rico, Chile, South Africa, Austria, Belgium
-
Alkermes, Inc.CompletedSchizophreniaUnited States
-
Alkermes, Inc.CompletedSchizophreniaUnited States